Loading...
•
Dec 31, 2022
Sutro Q4 2022 Earnings Report
Sutro reported its financial results for the full year 2022, recent business highlights, and select anticipated milestones.
Key Takeaways
Sutro Biopharma reported full year 2022 financial results, highlighting significant milestones in their pipeline and collaborations, and the appointment of Anne Borgman as Chief Medical Officer.
Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter.
Dr. Anne Borgman joined Sutro as Chief Medical Officer in February 2023.
Sutro expanded its relationship with Vaxcyte through an option agreement for the development and manufacturing rights for cell-free extract.
As of year-end 2022, Sutro had cash and investments of $302.3 million and shares of Vaxcyte common stock valued at $32.0 million, which together provide a projected cash runway into the second half of 2024.
Sutro
Sutro
Forward Guidance
Sutro plans to initiate REFRaME, a Phase 2/3 registration-directed study for patients with platinum-resistant ovarian cancer, in the second quarter of 2023.Preparations are underway for IND enabling studies for STRO-003, which we expect will be completed in the first quarter of 2024.